Drug Profile
Research programme: proteasome inhibitors - Principia Biopharma
Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Principia Biopharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 28 Sep 2020 Principia Biopharma has been acquired by Sanofi